US grants $1.6 billion to Novavax for COVID-19 vaccine project under Operation Warp Speed

vavax Inc. recently anunced that it will be receiving $1.6 billion from United States government for its COVID-19 vaccine programme. According to reports, funds will allow company to carry out vanced human trials of possible vaccine.

funding will also allow company to establish a manufacturing method that will make it possible for company to produce 100 million doses of possible COVID-19 vaccine as early as late 2020.

Re: COVID-19: NIH And DBT To Meet This Week; Review On Vaccine Candidates Likely

Biggest contribution under 'Operation Warp Speed'

Many pharmaceutical companies around world are embroiled in a race to develop COVID-19 vaccine. US President Donald Trump’s coronavirus vaccine programme has backed multiple companies like Johnson & Johnson and Merck & Co. but   $1.6 billion funding grant to vavax Inc. has emerged as biggest contribution me to a single company under Operation Warp Speed.

As per vavax Inc.'s statement, funds will allow company to test a viable vaccine candidate by this fall.  firm furr ded that it has around 30,000 subjects who have agreed to take part in trials. Earlier in May, vavax Inc also received $338 million from Coalition for Epidemic Preparedness Invations.

Re: China's Sivac Biotech Starts Phase III Trials Of Its Potential COVID-19 Vaccine

Chinese company in late-st trials

China’s leing provider of biopharmaceutical products, Sivac Biotech Ltd anunced on July 6 that it was entering phase III clinical trials sponsored by Instituto Butantan, Brazil, to test efficacy of its experimental COVID-19 vaccine.

As one of three pharmaceutical companies to reach late sts of trials, Sivac said it will recruit over 9,000 healthcare professionals to speed up process of developing potential cure for COVID-19, as per reports.

In collaboration with Butantan, a leing Brazilian producer of immubiological products and vaccines, Sivac has been given approval to run widescale trials by Brazilian National Regulatory ncy, Anvisa.

Re: US FDA Chief Refuses To Back Trump's 'year-end' Coronavirus Vaccine Claim

Re: COVID-19: Scientist At Science & Tech Min Opines 'mass Use Of Vaccine Unlikely Till 2021'